The Role of Angiogenesis Inhibitors in Hypertension: Following "Ariadne's Thread". (17th May 2018)

• Record Type: Journal Article
• Authors: Sanidas, Elias; Papadopoulos, Dimitris P; Velliou, Maria; Tsioufis, Kostas; Mantzourani, Marina; Iliopoulos, Dimitris; Perrea, Despoina; Barbetseas, John; Papademetriou, Vasilios
• Is Part Of: American journal of hypertension. Volume 31:Number 9(2018:Sep.)
• Page Start: 961
• Page End: 969
• Publication Date: 2018-05-17
• Subjects: blood pressure; cancer -- angiogenesis -- chemotherapy; hypertension; Hypertension -- Periodicals; 616.132005
• DOI: 10.1093/ajh/hpy087
• Languages: English
• ISSNs: 0895-7061

Abstract

Abstract: Arterial hypertension (HT) is one of the most frequently recorded comorbidities among patients under antiangiogenic therapy. Inhibitors of vascular endothelial growth factor and vascular endothelial growth factor receptors are most commonly involved in new onset or exacerbation of pre-existing controlled HT. From the pathophysiology point of view, data support that reduced nitric oxide release and sodium and fluid retention, microvascular rarefaction, elevated vasoconstrictor levels, and globular injury might contribute to HT. The purpose of this review was to present recent evidence regarding the incidence of HT induced by antiangiogenic agents, to analyze the pathophysiological mechanisms, and to summarize current recommendations for the management of elevated blood pressure in this field.